Sangamo Therapeutics, Inc.

NASDAQ:SGMO

Biotechnology

Healthcare
$0.18 +2.06%

+$0.00 today

Market cap
$70.43M
Beta
1.29
P/E (TTM)
-0.5
EPS (TTM)
-$0.32
52W Low $0.10High $0.77

Volume 0.61M

Average 9.53M

SGMO Effect of Forex Changes

Change in reported cash caused by exchange-rate movements on foreign-currency balances.

Sangamo Therapeutics, Inc.NASDAQ: SGMO

Effect of Forex Changes · Q1 FY2026 · quarter ended Mar 2026

Effect of forex changes turns negative

Q1 FY2026 effect of forex changes was -$766K, compared with $1.28M a year earlier. Trailing-twelve-month effect of forex changes was $3.55M. Over 3 fiscal years it compounded at +48.3% a year.

Context

  • Effect of forex changes amounted to 10.3% of revenue in FY2025, up 6.8 pp from a year earlier.
  • Effect of forex changes increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly effect of forex changes holds near -$766K or moves back toward the trailing-twelve-month quarterly average of $887K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$766K-2015.0% QoQ
Last fiscal yearDec 2025
$4.09M+299.8% YoY
LTMMar 2026
$3.55M+3612.9% YoY
Effect of Forex Changes past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-160.0%——
1 year+299.8%——
3-year CAGR+48.3%——
5-year CAGR——
10-year CAGR——

Effect of Forex Changes history

USD · from the cash flow

Latest · FY2025
4.09M USD
Year-over-year change
+299.8%

Effect of Forex Changes vs competitors

How SGMO compares with its peers on the latest reported figures

  • Peers report in different currencies, so effect of forex changes is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +3612.9% is the highest of 4, against a peer median of -73264.7%.
  • Effect of forex changes amounts to 10.3% of revenue for SGMO, versus a peer median of 0.0%.
SGMO Competitors
Effect of Forex Changes for SGMO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MOLNMolecular Partners AGLTM Mar 2026CHF 26.34M CHF-73264.7%——
IPHAInnate Pharma S.A.FY2025€7.41M EUR+1566.4%—265.7%
CDXSCodexis, Inc.LTM Mar 2026$4.97M USD——6.4%
SGMOSangamo Therapeutics, Inc.LTM Mar 2026$3.55M USD+3612.9%+48.3%10.3%
IMDXInsight Molecular Diagnostics Inc.LTM Mar 2026$234K USD——12.0%
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$11.48K USD-1148200.0%—0.6%
IVVDInvivyd, Inc.LTM Mar 2026$8K USD——0.0%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$0 USD——0.0%
OABIOmniAb, Inc.LTM Mar 2026$0 USD——0.0%
ARMPArmata Pharmaceuticals, Inc.LTM Mar 2026$0 USD——0.0%
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026$0 USD——0.0%
Peer median (excluding SGMO) —-73264.7%—0.0%

Competitors are the stored peer set for SGMO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(178.3M)(192.28M)(257.83M)(97.94M)(122.93M)
Depreciation & Amortization17.64M20.56M22.19M9.36M7.6M
Deferred Income Tax2.77M0(6.34M)00
Stock-Based Compensation32.96M31.65M27.36M12.38M9.08M
Change in Working Capital(101.9M)(82.32M)(164.03M)4.51M(4.22M)
Accounts Receivables(789K)2.34M(976K)953K155K
Inventory7.66M0000
Accounts Payables(7.66M)13.35M5.59M(14.17M)2.79M
Other Working Capital(101.11M)(98M)(168.65M)17.72M(7.17M)
Other Non-Cash Items(6.43M)(1.24M)153.8M4.55M13.27M
Operating Cash Flow(233.25M)(223.63M)(224.84M)(67.14M)(97.21M)
Capital Expenditures(23.28M)(20.17M)(21.16M)(267K)(102K)
Acquisitions (Net)(119K)(79.46M)01.95M0
Purchases of Investments(338.16M)(277.39M)(59.55M)00
Sales of Investments609.76M356.85M234.24M35.84M0
Other Investing Activities079.46M000
Investing Cash Flow248.2M59.29M153.53M37.52M(102K)
Debt Repayment00000
Common Stock Issued27.1M84.87M15.11M28.99M74.01M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities5.76M(209K)(518K)(614K)(3.26M)
Financing Cash Flow32.86M84.66M14.59M28.38M70.75M
Effect of Forex Changes(263K)1.25M1.48M(2.05M)4.09M
Net Change in Cash47.54M(78.43M)(55.24M)(3.29M)(22.47M)
Free Cash Flow(256.53M)(243.8M)(246M)(67.41M)(97.31M)

Sangamo Therapeutics, Inc.

NASDAQ:SGMO

Intrinsic Alpha fair value

Locked

Current Price

$0.18

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.